PPT-Elbasvir

Author : calandra-battersby | Published Date : 2017-06-12

Grazoprevir Ribavirin in TreatmentNaïve HCV GT 2 4 5 or 6 CSCAPE Phase 2 Treatment Naïve Brown A et al EASL 2015 Abstract P0771 Source Brown A et al

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Elbasvir" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Elbasvir: Transcript

Grazoprevir Ribavirin in TreatmentNaïve HCV GT 2 4 5 or 6 CSCAPE Phase 2 Treatment Naïve Brown A et al EASL 2015 Abstract P0771 Source Brown A et al EASL 2015 Abstract P0771. Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. C-WORTHY Study Part C: . grazoprevir. . + . elbasvir. ± RBV in genotype 1b. GZR + EBR + RBV. N = 30. N = 31. Design. W8. C-WORTHY/C. Vierling. . JM. EASL 2015, . Abs. . P0769 . >. 18 years. HCV genotype 1b. Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. . +/- Ribavirin in HCV Genotype 1, 4 or 6. C-EDGE Treatment Experienced (TE). Phase 3. . Treatment. . Experienced. Kwo. P, . et al. . EASL 2015. Abstract P0886.. Source: . Kwo. P et al. EASL 2015. Abstract P0886.. + . Grazoprevir. in . GT 1 . and Chronic Renal Disease. C. -SURFER. Phase 3. Treatment. Naïve and Treatment . Experienced. Roth D, . et al. Lancet . 2015;386:1537-45.. Source: Roth . D, et al. Lancet 2015;386:1537-45.. . + . Sofosbuvir. . in Treatment-Naïve HCV Genotype . 1 or 3. C-SWIFT. Phase . 2 . Treatment. . Naïve. Poordad. . F, . et al. . EASL 2015; Abstract O006.. Source: . Poordad. F, et al. EASL . 2015; Abstract . in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. Randomisation*. Open-label. >. 18 years. HCV genotype 1. HCV RNA ≥ 10,000 IU. /ml. Treatment naïve and . compensated cirrhosis (Child-Pugh A). or. Null responders to previous PEG-IFN + RBV, with or without cirrhosis. in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. Ribavirin in PI-experienced HCV GT1. C-SALVAGE. Phase . 2 . Treatment. . Experienced. (1) . Buti. M, et al. . Clin. Infect Dis. 2016;62:32-6. (2) . Forns. X, et al. J . Hepatol. . 2015;63:564-72. C-EDGE Treatment Naïve (TN). Phase 3. . Treatment. . Naïve. Zeuzem. S, . et al. . Ann Intern Med. 2015;163:1-13.. Source: . Zeuzem. S, et al. Ann Intern Med. 2015;163:1-13. .. Elbasvir-Grazoprevir. Medical Director, Austin Hepatitis Center. 1. Hepatitis C & PCP’s. 2. LACK OF AWARENESS. LACK OF APPROPRIATE ACTION. Expand Quantitative Landscape Study – Oct 2013 [Gilead Sciences]. 35-50% of PCP believe HCV can be cured. C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N = 21. N = 20. Design. W12. W18. SVR. 12. >. 18 years. HCV genotype . 3. HCV RNA ≥ 10 000 IU/mL. Treatment naïve . No cirrhosis. No HBV or HIV co-infection. HCV . GT 1,4, or 6 in PWID* on Opiate Agonist Therapy. C-EDGE CO-STAR. Phase . 2. Treatment. . Naïve. Dore G, . et al. . AALSD. 2015; Abstract 40. . Injection Drug Use. *PWID = Persons . W. ho . I.

Download Document

Here is the link to download the presentation.
"Elbasvir"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.